These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 9049234)

  • 21. Relationship of hepatitis C virus genotypes and viremia levels with development of hepatocellular carcinoma among Japanese.
    Tanaka K; Hirohata T
    Fukuoka Igaku Zasshi; 1998 Aug; 89(8):238-48. PubMed ID: 9778916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon: benefit beyond hepatitis therapy?
    Mallat DB; El-Serag HB
    Am J Gastroenterol; 2001 Dec; 96(12):3435-6. PubMed ID: 11774964
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus genotypes and the development of hepatocellular carcinoma.
    Stankovic-Djordjevic D; Djordjevic N; Tasic G; Dinic M; Karanikolic A; Pesic M
    J Dig Dis; 2007 Feb; 8(1):42-7. PubMed ID: 17261134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
    De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
    J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?].
    Harada H; Iga D; Arisaka Y; Mitsuhashi Y; Kamitsukasa H; Yagura M; Endou H; Kawashima H
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):754-8. PubMed ID: 7563870
    [No Abstract]   [Full Text] [Related]  

  • 27. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.
    Pradat P; Tillmann HL; Sauleda S; Braconier JH; Saracco G; Thursz M; Goldin R; Winkler R; Alberti A; Esteban JI; Hadziyannis S; Rizzetto M; Thomas H; Manns MP; Trepo C;
    J Viral Hepat; 2007 Aug; 14(8):556-63. PubMed ID: 17650289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular epidemiology of chronic hepatitis C (HCV) virus].
    Nitkiewicz J
    Przegl Epidemiol; 2004; 58(3):413-21. PubMed ID: 15730005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expert consensus on antiviral therapy to treat hepatitis B/C virus-related hepatocellular carcinoma].
    Ye S
    Zhonghua Gan Zang Bing Za Zhi; 2014 May; 22(5):321-6. PubMed ID: 25222971
    [No Abstract]   [Full Text] [Related]  

  • 31. Secondary prevention of hepatitis C virus-related hepatocellular carcinoma.
    Lin SM; Chu CM
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1475-7. PubMed ID: 16174061
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Shinkawa H; Hasegawa K; Arita J; Akamatsu N; Kaneko J; Sakamoto Y; Kokudo N
    Ann Surg Oncol; 2017 Oct; 24(11):3196-3202. PubMed ID: 28707053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hepatitis virus and hepatocellular carcinoma].
    Rosmorduc O; Paterlini P; Poupon R; Brechot C
    Gastroenterol Clin Biol; 1999 Mar; 23(3):363-75. PubMed ID: 10384341
    [No Abstract]   [Full Text] [Related]  

  • 34. [HCV genome in type C hepatocellular carcinoma].
    Yamada G
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):777-81. PubMed ID: 7563874
    [No Abstract]   [Full Text] [Related]  

  • 35. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of hepatitis C virus genotype 4.
    Abdo AA; Lee SS
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1233-9. PubMed ID: 15482528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current therapy of hepatitis C.
    de Knegt RJ
    Scand J Gastroenterol Suppl; 2006; (243):65-9. PubMed ID: 16782624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Uenishi T; Nishiguchi S; Tanaka S; Yamamoto T; Takemura S; Kubo S
    J Surg Oncol; 2008 Oct; 98(5):358-62. PubMed ID: 18646001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of splenic lymphoma after treatment of hepatitis C virus infection.
    Mazzaro C; Little D; Pozzato G
    N Engl J Med; 2002 Dec; 347(26):2168-70; author reply 2168-70. PubMed ID: 12501232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.